These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 39229963)
1. Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study. Svedbom A; Wennerström C; Hjelm F; Tjärnlund A; Ståhle M J Dermatolog Treat; 2024 Dec; 35(1):2398170. PubMed ID: 39229963 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864 [TBL] [Abstract][Full Text] [Related]
3. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD; JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279 [TBL] [Abstract][Full Text] [Related]
5. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial. Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180 [TBL] [Abstract][Full Text] [Related]
8. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404 [TBL] [Abstract][Full Text] [Related]
9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting. Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194 [TBL] [Abstract][Full Text] [Related]
10. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852 [TBL] [Abstract][Full Text] [Related]
11. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948 [TBL] [Abstract][Full Text] [Related]
12. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital. Sanz-Gil R; Pellicer A; Montesinos MC; Valcuende-Cavero F J Dermatolog Treat; 2020 Jun; 31(4):370-377. PubMed ID: 30924390 [No Abstract] [Full Text] [Related]
13. Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. Atalay S; van den Reek JMPA; van Vugt LJ; Otero ME; van de Kerkhof PCM; den Broeder AA; Kievit W; de Jong EMGJ BMC Dermatol; 2017 May; 17(1):6. PubMed ID: 28482858 [TBL] [Abstract][Full Text] [Related]
14. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425 [TBL] [Abstract][Full Text] [Related]
15. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective. Ross C; Marshman G; Grillo M; Stanford T Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697 [TBL] [Abstract][Full Text] [Related]
16. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ; J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928 [TBL] [Abstract][Full Text] [Related]
17. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621 [TBL] [Abstract][Full Text] [Related]
18. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study. Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924 [TBL] [Abstract][Full Text] [Related]
19. Biologic drug survival in Israeli psoriasis patients. Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888 [TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis. van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]